Cancer Drugs Rationing

If you’re a regular follower of this blog, you know that rationing is a standard policy of those countries with socialized medicine systems. Although our healthcare system today is not considered socialized medicine, this has been the goal of the Democratic Party, and Progressives in particular, since the days of President Teddy Roosevelt over 100 years ago.

When the Affordable Care Act (ObamaCare) was being debated in Congress in 2009, it was the intent of the Obama Administration to implement socialized medicine, but they knew the time was not right then for such a drastic change. Therefore, they settled for the ACA, which greatly increased the rolls of Medicaid, as a first step in that direction. More and more Americans now receive their healthcare through government-controlled programs and government-controlled prices.

The recently passed Inflation Reduction Act (a misnomer by any observer) has provided more government control over drug prices for those drugs paid for by Medicare. While this move will have very little impact on the actual prices paid by consumers, it will have a much larger impact on drug production and new drug innovation. That means fewer new drugs to combat cancer, diabetes, Alzheimer’s disease, and a host of other chronic diseases.

In a recent post, Insulin Prices – Who is the Villain?, I discussed the commonly-held belief of many politicians that drug companies are greedy and the government must watch out for the consumer lest they be overcharged for commonly-prescribed drugs. A recent Senate Health, Education, Labor, and Pensions (HELP) Committee hearing convened by Senator Bernie Sanders (the leader of the socialized medicine chorus) tried to promote these ideas, but was refuted strongly by the pharmaceutical industry and recent industry research. Here’s a quote from that blog post:

“According to the business services consultancy Deloitte, the average cost of developing a new drug among the top 20 global biopharmaceutical companies rose 15% ($298 million) last year to approximately $2.3 billion. Worse for drug developers, the return on investment reaped by these companies for new drugs and vaccines plunged last year by 82% to 1.2% – the lowest percentage recorded in the 13 years Deloitte launched its annual reports on biopharmaceutical companies R&D – from 6.8% in 2021 and 10.1% in 2010, the first year studied by Deloitte.”

The point of this post was that Progressives consider treatment of the elderly for Alzheimer’s Disease too expensive so they thwart efforts to develop new drugs and ration the use of currently available drugs. Now we are seeing the same rationing of care in the treatment of cancer.

In an editorial published in The Wall Street Journal, we learn of shortages of essential medicines because drugs prices are too low. They report the American Society of Health-System Pharmacists lists 301 drugs in short supply, up from 202 five years ago. These include many local anesthetics, basic hospital drugs, chemotherapy drugs and liquid albuterol for lung ailments.

The American Cancer Society warned this month that “first-line treatments for a number of cancers, including triple-negative breast cancer, ovarian cancer and leukemia often experienced by pediatric cancer patients,” are facing shortages that “could lead to delays in treatment that could result in worse outcomes.” Healthcare providers say they’re having to limit access to some drugs to the sickest patients. They can substitute therapeutic alternatives when possible, but this increases risk of medication errors and inferior results.

They say most drugs in short supply are older generics that are off-patent and complicated to make. Manufacturers have stopped producing them because profit margins are too thin, resulting in one or two suppliers. Generic manufacturers typically operate at full capacity and often use one production line to produce multiple drugs. If a plant experiences a quality or cross-contamination problem, an entire production line must shut down, which can affect multiple drugs for months. Other generic manufacturers can’t easily ramp up production.

What’s the reason for this problem?

The WSJ editors say, “Fewer branded drugs are in short supply because their manufacturers build more slack and resilience into supply chains. Higher profits give them more capital and a financial incentive to do so. And therein lies the underlying problem: Generic profits have shriveled owing to government efforts to reduce drug spending.” In other words, when you can’t make sufficient profit from making these drugs, no one wants to make them! Progressives seem to believe that drug companies should “take one for the team” and just make these drugs even at a loss!

This reminds me of one of the first and most important lessons of adulthood – “There’s no such thing as a free lunch.” You can’t expect anyone to lose money doing anything; you must allow everyone to make a reasonable, fair profit for their investment of time and money. But Progressives like Sen. Sanders still believe “There is an enormous amount of greed in the system.”

Mandatory Medicaid rebates have also squeezed generic drug margins. Medicaid is the top payer for many generic drugs. But low reimbursements by government health systems are a global problem, and manufacturers with plants in Europe cut production amid last year’s energy price spike. The FDA recently flagged problems at a major Indian plant and halted exports. Politicians criticize generic companies for shifting production to India and China to reduce costs, but the alternative for many would be going out of business, which Illinois-based Akorn Pharmaceuticals did this past winter.

WSJ editors say, “The solution is for government to pay more for drugs, which politicians oppose because it will increase healthcare spending. Instead, they want to squeeze more money out of the pharmaceutical industry, which will exacerbate shortages.” Politicians always want a foil to be the brunt of their angst and the pharmaceutical industry is their favorite foil. But blaming them won’t solve the drug shortage or provide the drugs needed to treat Americans.

FDA’s Role in Opioid Crisis

We have an opioid crisis in America. This is not news – and it didn’t begin with the influx of Fentanyl across the Mexican border. That’s only the latest edition of this ongoing problem and the most fatal.

At a recent April subcommittee hearing, Food and Drug Administration Commissioner Robert Califf blamed the pharmaceutical industry for a lack of nonaddictive nonopioid pain medications. In his telling, the FDA is waiting with open arms for any new analgesics that industry may develop: “We need to do everything we can do to push industry and make this happen.”

That’s a noble perspective coming from someone within the industry himself. But there’s much more to this story. Fortunately, we have an insider’s perspective from the pharmaceutical industry. Charles L. Hooper, writing for The Wall Street Journal, formerly worked for Syntex, a large pharmaceutical company. Hooper says this about FDA Commissioner Califf’s statement: “He’s partially right: The government should commit itself to supporting private innovation. But it is disingenuous to blame industry for a dearth of treatments. Consider the evolution of the drug Toradol – generic name ketorolac – a case study in the agency’s propensity to scuttle effective medicine.”

Several decades ago, Syntex discovered and developed ketorolac: a nonsteroidal anti-inflammatory drug, or NSAID, used to provide morphine levels of pain relief without the same abuse potential as opioids. The FDA approved the drug in 1989, and it soon hit the market under the brand name Toradol IV/IM, joining other popular though less potent NSAIDs such as Advil, Motrin, and aspirin.

Before approval, an FDA employee suggested that Toradol IV/IM be given with a loading dose – that is, twice the standard amount. Against their better judgment, Syntex employees complied. The loading dose turned out to be a disaster: Gastrointestinal bleeding killed 97 patients worldwide between 1990 and 1993. The FDA subsequently changed Toradol IV/IM’s label and instructions, eliminating the guidance for double dosages, but by that point the reputational damage had been done.

While injectable Toradol IV/IM continues to be used in emergency rooms and post-op recovery rooms, many physicians remain skeptical of regular doses. When Syntex developed an oral version and submitted it to the FDA, the agency approved it, but gave it a label that essentially precluded its common use – they limited its dosage to about a third of its effective amount and imposed a strict limit of five days usage – also mandating the oral tablets follow an injection or intravenous dose of Toradol IV/IM. In other words, you can’t get Toradol oral treatment from your pharmacist unless you’ve received an injection of it in the emergency room or operating room.

A personal word is warranted here: I have suffered six times in my life with the pain of kidney stones. As anyone who has shared that experience can testify, kidney stones can produce some of the most excruciating pains imaginable. I have received opioid treatments including fentanyl and morphine. While both can be effective, they are usually accompanied by severe constipation – a regular side effect of opioids. Toradol has provided me with the same pain relief as morphine but without the constipation. I carry Toradol tablets in my travel kit and had to use them recently when I experienced another kidney stone during a trans-Atlantic flight.

Hooper says, “A bottle of ketorolac oral tablets should be in almost every American’s medicine cabinet today. It probably never will be. Now that ketorolac is generic, there’s no way to make money on getting the proper dose approved. The FDA could admit that it was wrong and adjust its approval accordingly – but that would require a healthy dose of humility. If Mr. Califf is serious about doing everything to bring beneficial drugs to market, here is a perfect place to start.”

Cannabis and Schizophrenia

 

 

Surprise! Cannabis use has been linked to schizophrenia, especially in young men. This news has been posted in several major news outlets, including The New York Post. The only thing newsworthy about this story is it qualifies as news.

As a physician, I have been aware of this connection since medical school, nearly fifty years ago! But politicians have been pressured to ignore this information since recreational marijuana use has been legalized now in 21 states and 18 more have legalized medical usage. With so many states making it possible to use marijuana, what could go wrong?

I went to college at The University of Colorado in the 1970s. The Boulder campus was filled with potheads and others in the hippie culture. Most of these people were not actually students, but their presence was ubiquitous and the pathology of their minds was undeniable; and that was before the much higher concentrated cannabis was available. Depression and schizophrenia were present then; it’s no surprise they’re even more common today.

The most recent research study was published May 4 in the journal Psychological Medicine. It found that a shocking 30% of schizophrenia cases among men aged 21 to 30 could have been thwarted if they had averted cannabis use disorder (CUD). Scientists examined recent cases of schizophrenia, an abnormal interpretation of reality resulting in hallucinations, delusions or disordered thinking. The study’s authors stated that in 2021, CUD played an integral role in 15% of cases occurring in men aged 16 to 49, and in 4% of cases affecting women in the same age range. This new study examined data concerning 6.9 million people ages 16 to 49 collected in Denmark from 1972 to 2021.

CUD is defined by the Centers for Disease Control and Prevention (CDC) as the inability to stop using marijuana despite negative impacts on one’s health and social life. (That’s a fancy way of saying marijuana is addictive.) According to the CDC, it affects 3 in 10 marijuana smokers. It is not surprising that men are at more risk for developing schizophrenia when smoking marijuana since the same male preponderance is found in non-smokers of marijuana as well.

Excessive use of marijuana in teens is especially dangerous since it can impact brain development and even cause some changes to its anatomy. “The brain is at its peak developmental years from 12 to 20,” said Dr. Scott Krakower, a psychiatrist at Northwell Health’s Zucker Hillside Hospital in an interview with The New York Post. “When marijuana comes into the picture, the normal brain development is impaired.”

“There could be changes to the overall neuroplasticity and neurocircuitry. . . changes to serotonin, changes to dopamine, histamine, all these things are responsible for executive functioning and for how we perceive the world,” he continued. “When cannabis oversaturates the system it can trigger higher levels of anxiety, cognitive delays, and memory loss.” 

Teens are also more likely to develop a problem with the drug. According to a report by the National Institute on Drug Abuse published in March, 2021, those aged 12 to 17 are more apt than those aged 18 to 25 to become addicted to marijuana within a year after using it for the first time.

The Danish study determined that while cannabis use disorder is not responsible for most schizophrenia cases in Denmark specifically, marijuana consumption has contributed to a rise in schizophrenia in the last 50 years. Researchers say one possible reason is that cannabis is both more accessible and more powerful than ever. They found that the amount of THC – the major psychoactive component – in weed in the U.S. rose from 10% in 2009 to 14% in 2019. In Denmark it was 13% in 2006 and 30% in 2016.

For comparison, the THC in weed when I was in college was typically less than 1.5% in the 1970s and 1980s, according to previous research published int the Journal of Forensic Sciences. Today, some cannabis products contain THC concentrations upward of 30%. Some concentrated products such as oils and edibles can have above 95%.

Dr. Krakower says, “A lot of these products are mislabeled. When you’re looking at the weed market, nothing is regulated – you always have to know in the back of your head if you’re having 5mg you might be having 10 or 15 mg- there’s just no way of knowing. The problem is, people forget that marijuana is still a substance no matter how we look at it. Parents need to understand that it’s not healthy.”

That’s not news. I could have told you that 50 years ago!